Milestone in the treatment of anaemia in chronic lymphocytic leukaemia

International Clinical Trial Shows Alternative to Standard Treatment of Myelodysplastic Neoplasms

In people with myelodysplastic neoplasms (MDS), a usually benign form of chronic lymphocytic leukaemia, the body produces too few functional blood cells. Affected individuals suffer from anaemia - a lack of red blood cells or haemoglobin - which can be a precursor to acute leukaemia. Compared to the standard treatment, luspatercept can increase haemoglobin levels in MDS patients and help them to avoid blood transfusions. These are the findings of an international clinical trial led by Professor Uwe Platzbecker from Leipzig University and the University of Leipzig Medical Center in collaboration with a large international research team. ...